Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05942300 · ClinicalTrials.gov registry record · Phase 1

CPI-0209 Plus Carboplatin in Patients With Platinum Sensitive Recurrent Ovarian Cancer

A Phase 1 study of Recurrent Ovarian Cancer, sponsored by Lan Coffman.

Recruiting
Registry status
Phase 1
Development phase
30
Enrollment target
1
Study location

NCT05942300: Recruiting Phase 1 study of Recurrent Ovarian Cancer, sponsored by Lan Coffman.

NCT05942300 is a Phase 1 study of Recurrent Ovarian Cancer that is actively recruiting participants, run by Lan Coffman. The registered enrollment target is 30 participants, below the 186-participant average among 6 other Recurrent Ovarian Cancer trials with a reported enrollment target (84% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05942300, a Phase 1 study of Recurrent Ovarian Cancer, is actively recruiting participants, sponsored by Lan Coffman.

RECRUITING
Registry status
Phase 1
Development phase
30 participants
Enrollment target
1
Study location

Study Summary

This is a clinical trial using CPI-0209 in combination with Carboplatin chemotherapy followed by CPI-0209 maintenance in patients with platinum sensitive, recurrent ovarian cancer.

Primary Outcome

MTD will be determined via Dose-limiting toxicity (DLT)s defined as any grade 3-4 non-hematological or grade 4 hematological toxicity at least possibly related to the treatment, occurring during the first two cycles of treatment and per Cancer Therapy Evaluation Program (CTEP) Common Terminology Criteria for Adverse Events (CTCAE) version 5.

Conditions Studied

Recurrent Ovarian Cancer

Interventions

  • DRUG carboplatin
  • DRUG CPI-0209

Study Locations (1)

Pennsylvania

  • Magee-Womens Research Institute / UPMC Magee Womens Hospital - Pittsburgh

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2024-01-30
Est. Completion 2028-12-31
Phase Phase 1
Lan Coffman

1 total trials

What NCT05942300 shows while recruiting

NCT05942300 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 186-participant average among 6 other Recurrent Ovarian Cancer trials with a reported enrollment target (84% lower).

The record links to 1 condition, with Recurrent Ovarian Cancer appearing as the primary indexed condition, and to 2 interventions - of which carboplatin is the first listed.

NCT05942300 reports a single indexed study location in Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT05942300 about?

NCT05942300 is a clinical study titled "CPI-0209 Plus Carboplatin in Patients With Platinum Sensitive Recurrent Ovarian Cancer". This is a clinical trial using CPI-0209 in combination with Carboplatin chemotherapy followed by CPI-0209 maintenance in patients with platinum sensitive, recurrent ovarian cancer.

What is the current status of trial NCT05942300?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2024-01-30. Estimated completion is 2028-12-31.

What conditions does trial NCT05942300 study?

This clinical trial studies the following conditions: Recurrent Ovarian Cancer.

What interventions are being tested in trial NCT05942300?

The interventions under investigation include: carboplatin (DRUG), CPI-0209 (DRUG).

Who is sponsoring clinical trial NCT05942300?

This trial is sponsored by Lan Coffman, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05942300 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Recurrent Ovarian Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00977977 · 30 participants · Phase 2

    Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

  • NCT01459107 · 30 participants · Phase 2

    Human Upper Extremity Allotransplantation

  • NCT01666080 · 30 participants · NA

    Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)

  • NCT01720836 · 30 participants · Phase 1

    Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT05942300

Source: ClinicalTrials.gov NCT05942300, the US trial registry maintained by the National Library of Medicine. NCT05942300 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.